Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.75
-0.43 (-0.32%)
Streaming Delayed Price
Updated: 11:19 AM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Today 4:21 EDT
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Via
Benzinga
Looking At Novo Nordisk's Recent Unusual Options Activity
August 27, 2024
Via
Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
August 27, 2024
The single-dose vials will also increase supply, the drug giant says.
Via
Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
August 27, 2024
Shareholders don't have too much to fear -- yet.
Via
The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
What the Options Market Tells Us About Novo Nordisk
August 22, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
August 20, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Novo Nordisk Through 8 Analysts
August 19, 2024
Via
Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
August 26, 2024
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Via
MarketBeat
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
August 26, 2024
Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senator Sanders and experts remain critical as a Senate hearing looms next...
Via
Benzinga
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
August 25, 2024
Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
Via
The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000
August 24, 2024
There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns.
Via
The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
August 23, 2024
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via
News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
August 23, 2024
Ozempic remains on top in the GLP-1 drug market -- but for how long?
Via
The Motley Fool
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
August 23, 2024
Vertex Pharmaceuticals has a lot going for it.
Via
The Motley Fool
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
August 21, 2024
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments.
Via
Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish...
Via
Benzinga
Topics
Economy
Exposures
Supply Chain
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
August 21, 2024
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.
Via
The Motley Fool
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization...
Via
Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
August 19, 2024
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities...
Via
Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
August 19, 2024
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its...
Via
Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
August 19, 2024
Impediments to growth are melting away while new opportunities begin to rise.
Via
The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
August 18, 2024
Eli Lilly has a lot going for it.
Via
The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
August 18, 2024
Should Novo Nordisk and Eli Lilly investors be worried about Roche?
Via
The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
August 18, 2024
This list of top-selling drugs could look drastically different in a few years.
Via
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy?
August 17, 2024
The biotech could be worth a lot more in 10 years.
Via
The Motley Fool
3 Fantastic Growth Stocks to Buy in August
August 17, 2024
These stocks should keep up their winning ways.
Via
The Motley Fool
Could Viking Therapeutics Become the Next Novo Nordisk?
August 17, 2024
Given this biotech's ascent, its odds of becoming a giant are better than most.
Via
The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
August 16, 2024
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.